{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T05:45:05.720311+00:00","company":{"ticker":"VYNE","cik":1566044,"company_name":"VYNE Therapeutics Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"793c983085e2fd16e30bb4563a31c34945ee08ac","cik":1566044,"ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","filed_at":"2026-03-11T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-09-07","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2026-03-11","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"VYNE Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 11, 2026, the Company received a letter (the “Extension\nNotice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price\nrequirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance\nwith the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement\nfor market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the\nexception of t","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-26-026439","anchor_url":"https://secwatch.observer/filing/0001104659-26-026439#claim-793c983085e2fd16e30bb4563a31c34945ee08ac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/0001104659-26-026439-index.htm"},{"fact_type":"material_agreement","fact_key":"569e144a31562ea2d9c10062160c2a65c8eac01d","cik":1566044,"ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","filed_at":"2026-01-30T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"Yarrow Merger Sub Corp. and Yarrow Bioscience, Inc.","effective_date":"2026-01-30","item_codes_triggered":["1.01"],"value_text":null},"claim":"VYNE Therapeutics Inc. amended Amendment to Agreement and Plan of Merger and Reorganization with Yarrow Merger Sub Corp. and Yarrow Bioscience, Inc. (effective 2026-01-30).","evidence_excerpt":"On January 30, 2026, VYNE Therapeutics Inc., a Delaware corporation (“VYNE”), Yarrow Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of VYNE (“Merger Sub”), and Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), entered into an amendment (the “Amendment”) to that certain Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the “Merger Agreement”), by and among VYNE, Merger Sub and Yarrow.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-008642","anchor_url":"https://secwatch.observer/filing/0001104659-26-008642#claim-569e144a31562ea2d9c10062160c2a65c8eac01d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926008642/0001104659-26-008642-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a898fe6bf61dfd5c5ca58f124ffd3a405094dfc7","cik":1566044,"ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-09-12T23:59:59+00:00","payload":{"company_response":"considering all available options to regain compliance","compliance_status":"deficient","cure_deadline":"2026-03-10","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"minimum closing bid price of $1.00 per share for 30 consecutive business days","notice_date":"2025-09-11","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) and Nasdaq Listing Rule 5810(c)(3)(A)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"VYNE Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 11, 2025, VYNE Therapeutics Inc. (the “Company”)\nreceived notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement\nto maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price\nof the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification\ndoes not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-089531","anchor_url":"https://secwatch.observer/filing/0001104659-25-089531#claim-a898fe6bf61dfd5c5ca58f124ffd3a405094dfc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925089531/0001104659-25-089531-index.htm"},{"fact_type":"earnings_release","fact_key":"dfb67ce79655a5911c95ff28b00e79c4d184eee8","cik":1566044,"ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.15","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$6.2 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$0.1 million"},"claim":"VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.","evidence_excerpt":"financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021971","anchor_url":"https://secwatch.observer/filing/0001628280-24-021971#claim-dfb67ce79655a5911c95ff28b00e79c4d184eee8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/0001628280-24-021971-index.htm"}]}